Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design

Affiliations

¹ Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA.

Editorial

Chul Kim et al. Ann Transl Med. 2016 Dec.

. 2016 Dec;4(23):466.

doi: 10.21037/atm.2016.11.48.

¹ Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. Papadimitrakopoulou V, et al. J Clin Oncol. 2016 Oct 20;34(30):3638-3647. doi: 10.1200/JCO.2015.66.0084. J Clin Oncol. 2016. PMID: 27480147 Free PMC article.

1. Thomas A, Liu SV, Subramaniam DS, et al. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015;12:511-26. 10.1038/nrclinonc.2015.90 - DOI - PubMed
1. U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. 2016; Accessed February 26, 2016. Available online: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174
1. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97. 10.1056/NEJMoa1311107 - DOI - PMC - PubMed
1. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71. 10.1056/NEJMoa1406766 - DOI - PMC - PubMed
1. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010;16:691-8. 10.1158/1078-0432.CCR-09-1357 - DOI - PubMed